Company Profile

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE1505.50-8.6 (-0.57 % )
PREV CLOSE (Rs.) 1514.10
OPEN PRICE (Rs.) 1517.20
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2808
TODAY'S LOW / HIGH (Rs.)1500.85 1519.50
52 WK LOW / HIGH (Rs.)1379 1765.95
NSE1504.95 -8.65 (-0.57 % )
PREV CLOSE(Rs.) 1513.60
OPEN PRICE (Rs.) 1515.00
BID PRICE (QTY) 1504.95 (1 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 35744
TODAY'S LOW / HIGH(Rs.) 1501.00 1519.95
52 WK LOW / HIGH (Rs.)1376 1767.4

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.99
TTM EPS (Rs.) 21.66
P/E Ratio 69.58
Book Value (Rs.) 96.71
Face Value (Rs.) 10
MCap (Rs. in Mn) 255337.24
Price/Earning (TTM) 57.74
Price/Sales (TTM) 7.69
Price/Book (MRQ) 15.59
PAT Margin (%) 11.20
ROCE (%) 32.95
Incorporation Year : 1924

Management Info :

R S Karnad - Chairman S Venkatesh - Managing Director

Registered Office :

Address : Dr Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone : 022-24959595

Email : askus@gsk.com

Website : www.gsk-india.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
27Jul07-27-2021$GlaxoSmithKline Pharmaceuticals to transfer rights of Iodex and Ostocalcium brands to GSK Asia GlaxoSmithKline Pharmaceutic

GlaxoSmithKline Pharmaceuticals has decided to transfer its rights in relation to the Iodex and Ostocalcium brands to GlaxoSmithKline Asia, for an aggregate consideration of Rs 1649 crore. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals.

GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV. 

GlaxoSmithKline Pharmaceuticals has decided to transfer its rig..
27Jul07-27-2021$Vodafone Idea, Biocon and Bajaj Auto to see some action today Vodafone Idea, Biocon and Ba

Vodafone Idea’s (VIL) enterprise arm -- Vodafone Idea (VIL), Vi Business has lined up a range of new postpaid plans for corporate customers. The upgraded plans will be bundled with range of exclusive benefits. Vi 'Business Plus' plans would enable corporate customers to strike the right balance between business objectives and employee preferences in an increasingly hybrid working environment.

U.S. based Adagio Therapeutics has granted an exclusive license to Biocon Biologics, a fully integrated biosimilars company and a subsidiary of Biocon, to manufacture and commercialize an antibody treatment based on ADG20 for India and select emerging markets. ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge.

Bajaj Auto has reached an agreement its Austrian partner Pierer Industrie AG for simplifying their shareholding pattern in premium bike maker KTM through a two-step transfer of their stakes to a new holding company.

GlaxoSmithKline Pharmaceuticals has decided to transfer its rights in relation to the Iodex and Ostocalcium brands to GlaxoSmithKline Asia, subject to shareholder approval, for an aggregate consideration of Rs 1649 crore. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals.

Prataap Snacks has commenced commercial production at its newly set up Unit situated at Mouza - New Kolorah, Police Station - Domjur, District - Howrah, West Bengal on July 26, 2021.

Sharika Enterprises has received the order from LS Cable India for Supply of Cable Accessories amounting 1.67 crore Including Taxes. Earlier, the company had received the order amounting Rs 4.23 crore.

Tata Power has committed to reducing emissions in alignment with the Science-Based Targets initiative (SBTi). SBTi is a project which drives ambitious climate action in the private sector by enabling companies to set science-based emissions reduction targets.

Vodafone Idea’s (VIL) enterprise arm -- Vodafone Idea (VIL),..
06Jul07-06-2021$ Board Meeting Intimation for Un- Audited Financial Results For The First Quarter Ended
30Th June 2021
Board Meeting Intimation fo
GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 ,inter alia, to consider and approve Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations,2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 25th July 2021, inter-alia, to consider approval of Un-audited financial results for the first quarter ended 30th June 2021 .
GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the m..
01Jun06-01-2021$GlaxoSmithKline Pharmaceuticals informs about AGM GlaxoSmithKline Pharmaceutic
GlaxoSmithKline Pharmaceuticals has informed that the company will hold the 96th Annual General Meeting ('AGM') on Tuesday, 27th July, 2021, through Video Conferencing/ Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India; The Board of Directors has recommended a total dividend of Rs 30 per share for the financial year ended 31st March, 2021 on Equity Shares of Re 10 each, subject to the approval of shareholders at the forthcoming Annual General Meeting.

The above information is a part of company’s filings submitted to BSE.
GlaxoSmithKline Pharmaceuticals has informed that the company w..
19May05-19-2021$Glaxosmithkline Pharmaceuticals informs about annual secretarial compliance report Glaxosmithkline Pharmaceutic

In compliance with the provisions of Regulation 24A of SEBI LODR Amendment Regulations, 2018, read with SEBI Circular dated February 08, 2019, Glaxosmithkline Pharmaceuticals has informed that it has enclosed the Annual Secretarial Compliance Report of the Company for the financial year ended 31st March 2021.

The above information is a part of company’s filings submitted to BSE.

In compliance with the provisions of Regulation 24A of SEBI LOD..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit12043575.6
Gross Profit 1639.2 5497.3
Operating Profit 1824.28051.4
Net Sales 7734.631937.3
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20792.55 (1.20%)
M.Cap ( in Cr)
44123.75
Piramal Enterprises (BSE)
 2612.25 (4.37%)
M.Cap ( in Cr)
62348.49
Dr. Reddy's Lab (BSE)
 4854.85 (1.64%)
M.Cap ( in Cr)
80783.01
Amrutanjan Healthcar (BSE)
 851.60 (9.89%)
M.Cap ( in Cr)
2489.28
Alkem Laboratories (BSE)
 3860.45 (1.95%)
M.Cap ( in Cr)
46164.05
Shareholding Pattern More
PROMOTERS 75 %
MUTUAL FUNDS/UTI 4.07 %
NON-INSTITUTION 12.46 %
FI/BANKS/INSURANCE 1.44 %
FII 0 %
GOVERNMENT 0 %
F & O Quotes